Reinhart Partners LLC. Has $4.44 Million Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Reinhart Partners LLC. trimmed its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 30.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 49,362 shares of the medical equipment provider’s stock after selling 21,324 shares during the quarter. Reinhart Partners LLC.’s holdings in Zimmer Biomet were worth $4,439,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Border to Coast Pensions Partnership Ltd boosted its holdings in Zimmer Biomet by 6.5% during the third quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock valued at $35,506,000 after purchasing an additional 22,104 shares in the last quarter. National Pension Service boosted its holdings in Zimmer Biomet by 4.5% during the third quarter. National Pension Service now owns 393,476 shares of the medical equipment provider’s stock valued at $38,757,000 after purchasing an additional 16,928 shares in the last quarter. AMG National Trust Bank raised its stake in shares of Zimmer Biomet by 29.1% in the third quarter. AMG National Trust Bank now owns 50,359 shares of the medical equipment provider’s stock valued at $4,960,000 after acquiring an additional 11,339 shares during the last quarter. Skandinaviska Enskilda Banken AB publ raised its stake in shares of Zimmer Biomet by 47.5% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 62,079 shares of the medical equipment provider’s stock valued at $6,115,000 after acquiring an additional 19,996 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Zimmer Biomet by 6.1% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 399,826 shares of the medical equipment provider’s stock valued at $39,383,000 after acquiring an additional 22,992 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ZBH has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Tuesday, February 10th. UBS Group reiterated a “sell” rating and issued a $89.00 target price on shares of Zimmer Biomet in a research note on Wednesday, February 11th. William Blair initiated coverage on shares of Zimmer Biomet in a research note on Friday, February 20th. They issued a “market perform” rating for the company. Finally, Robert W. Baird set a $92.00 target price on shares of Zimmer Biomet in a research note on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $102.70.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the sale, the senior vice president owned 10,224 shares in the company, valued at approximately $967,803.84. The trade was a 20.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the sale, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. The trade was a 15.50% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is currently owned by corporate insiders.

Zimmer Biomet Stock Up 0.9%

NYSE:ZBH opened at $83.70 on Wednesday. The stock’s fifty day moving average price is $87.82 and its two-hundred day moving average price is $90.61. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. The company has a market cap of $16.19 billion, a price-to-earnings ratio of 21.74, a P/E/G ratio of 1.92 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The firm had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. During the same quarter in the prior year, the business earned $1.81 EPS. The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.